Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][2][3] - The collaboration aims to enhance ANEMOCYTE's offerings by utilizing Genenta's established LVV Plasmid DNA technology, which is based on foundational research by Professor Luigi Naldini [2][3] - This partnership is expected to support the development of advanced therapy programs across the life sciences industry, ensuring clients have access to reliable and scalable solutions [3] Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing T cell responses and breaking immune tolerance [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has focused on the production of Plasmid DNA. The partnership leverages Genen ...